Climb Bio raises $110M in private placement of common stock and pre-funded warrants

Climb Bio, Inc.

Gross proceeds of ~$110M from 9.481M shares at $9.50 and 2.106M pre-funded warrants at $9.4999 each.
Closing expected April 29; participants include RA Capital, Adage Capital, Cormorant, and others.
Proceeds to fund late-stage development of budoprutug and CLYM116 for immune-mediated diseases.
Company to file resale registration statement within 45 days after closing.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.